AMN Life Science Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: AMN Life Science Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $8.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AMN Life Science Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $8.7M Trade | TransData Nexus

AMN Life Science Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $8.7M Total Trade · DGFT Verified

AMN Life Science Private Limited is an Indian pharmaceutical exporter with a total trade value of $8.7M across 2 products in 1 therapeutic categories. Based on 203 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amoxicillin ($4.6M), Ampicillin ($4.0M), .

AMN Life Science Private Limited — Export Portfolio & Destination Treemap

AMN Life Science Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is AMN Life Science Private Limited? — Company Overview & Market Position

AMN Life Science Private Limited, established on 30 May 2003, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2003PTC140663. As of 31 March 2017, AMN Life Science reported an authorized capital of ₹200 lakhs and a paid-up capital of ₹200 lakhs. The company's operations are active, with its last Annual General Meeting (AGM) held on 30 September 2017.

AMN Life Science specializes in the manufacturing and marketing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's product portfolio is concentrated in the antibiotic therapeutic category, with a focus on amoxicillin and ampicillin formulations. This strategic focus has enabled AMN Life Science to establish a significant presence in the global pharmaceutical market.

What Does AMN Life Science Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Amoxicillin$4.6M 2

Product Portfolio — Top 2 by Export Value

AMN Life Science Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$4.6M	122	0.8%	15
2	Ampicillin	Antibiotics	$4.0M	81	2.8%	4

AMN Life Science Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $8.7M. The top category is Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

AMN Life Science Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

AMN Life Science operates manufacturing facilities in India, adhering to stringent quality standards to produce a diverse range of pharmaceutical formulations. The company holds certifications from the European Union (EU) and the World Health Organization (WHO), ensuring compliance with Good Manufacturing Practices (GMP). These certifications reflect AMN Life Science's commitment to producing high-quality medicines for both domestic and international markets.

3Key Leadership

The leadership team at AMN Life Science Private Limited comprises:

Ashish Vijay Khemka: Managing Director, appointed on 30 May 2003.

Reshma Ashish Khemka: Director, appointed on 6 February 2006.

Under their guidance, the company has expanded its product offerings and strengthened its presence in emerging markets.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does AMN Life Science Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

AMN Life Science has made significant strides in regulated markets, obtaining approvals from health authorities in the European Union (EU), United Kingdom (UK), Australia, and Canada. The company has secured over 150 marketing authorizations (MAs) in these regions, demonstrating its commitment to meeting international regulatory standards.

In the United States, AMN Life Science has registered its manufacturing facilities with the Food and Drug Administration (FDA), indicating its readiness to supply the U.S. market. The company has also filed Abbreviated New Drug Applications (ANDAs) for its products, aiming to offer affordable generic alternatives to branded medications. These efforts underscore AMN Life Science's dedication to expanding its footprint in the U.S. pharmaceutical market.

2Emerging Markets

AMN Life Science has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company has registered over 500 products across these regions, tailoring its portfolio to meet the specific healthcare needs of each market.

The World Health Organization's prequalification program has facilitated AMN Life Science's access to these markets, enabling the company to supply quality-assured medicines to underserved populations. This initiative aligns with AMN Life Science's mission to provide affordable and effective healthcare solutions globally.

AMN Life Science Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

AMN Life Science has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, seeking approval to market generic versions of branded medications in the U.S.

The FDA's inspection history of AMN Life Science's facilities reflects the company's commitment to maintaining high-quality manufacturing practices. While specific inspection outcomes are not publicly disclosed, the company's proactive engagement with the FDA underscores its dedication to meeting stringent regulatory requirements.

2WHO & EU GMP

AMN Life Science holds certifications from the World Health Organization (WHO) and the European Union (EU), affirming its adherence to Good Manufacturing Practices (GMP). These certifications are crucial for the company's operations in international markets, as they ensure the production of safe and effective pharmaceutical products.

3CDSCO & Indian Regulatory

AMN Life Science Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the antibiotic formulation segment, AMN Life Science faces competition from established Indian pharmaceutical companies such as Cipla, Sun Pharma, and Lupin. These competitors have extensive product portfolios and established market presences.

AMN Life Science differentiates itself by focusing on specific antibiotic formulations like amoxicillin and ampicillin, allowing for specialized expertise and quality assurance. While the company holds a smaller market share compared to its larger competitors, its strategic focus and quality certifications position it as a reliable supplier in the global pharmaceutical market.

2Key Differentiators

AMN Life Science's key differentiators include its specialized focus on antibiotic formulations, adherence to international quality standards, and a robust regulatory compliance record. The company's certifications from WHO and EU GMP underscore its commitment to producing high-quality medicines.

3Strategic Position

AMN Life Science's current strategic direction emphasizes the production and marketing of generic pharmaceutical formulations, particularly in the antibiotic category. The company's expansion into regulated markets, including the EU, UK, Australia, and Canada, reflects its commitment to offering affordable healthcare solutions globally.

Buyer Due Diligence Brief — Evaluating AMN Life Science Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

AMN Life Science has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on antibiotic formulations. The company's export volume and consistency are supported by its certifications from WHO and EU GMP, indicating reliable manufacturing practices.

The company's proactive approach to obtaining regulatory approvals and maintaining compliance with international standards further enhances its reliability as a supplier. AMN Life Science's strategic focus on specific therapeutic areas allows for specialized expertise, contributing to the quality and consistency of its products.

2Certifications to Verify

Importers should verify the following certifications when considering AMN Life Science as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulatory standards.

WHO GMP Certification: Verify the company's certification from the World Health Organization to ensure adherence to international Good Manufacturing Practices.

Frequently Asked Questions — AMN Life Science Private Limited

How many pharmaceutical products does AMN Life Science Private Limited export from India?

AMN Life Science Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Amoxicillin ($4.6M), Ampicillin ($4.0M). Total export value is $8.7M.

What is AMN Life Science Private Limited's total pharmaceutical export value?

AMN Life Science Private Limited's total pharmaceutical export value is $8.7M, based on 203 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does AMN Life Science Private Limited cover?

AMN Life Science Private Limited exports across 1 therapeutic categories. The largest are Antibiotics (100.0%, 2 products).

Get Full AMN Life Science Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.